Research advances in tenofovir alafenamide fumarate in treatment of special chronic hepatitis B
10.3969/j.issn.1001-5256.2023.01.024
- VernacularTitle:富马酸丙酚替诺福韦治疗特殊慢性乙型肝炎的相关进展
- Author:
Yuwen SONG
1
;
Lili SHA
1
;
Lizhen CHEN
1
;
Mengkun LI
1
;
Yurong WANG
2
;
Yongning XIN
1
Author Information
1. Department of Infectious Diseases, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao, Shandong 266011, China
2. Qingdao Clinical Medical College Affiliated to Nanjing Medical University, Nanjing 210000, China
- Publication Type:Review
- Keywords:
Hepatitis B, Chronic;
Hepatitis B virus;
Tenofovir Alafenemide Fumarate;
Therapeutics
- From:
Journal of Clinical Hepatology
2023;39(1):156-161
- CountryChina
- Language:Chinese
-
Abstract:
There are a large number of individuals with HBV infection in China, which seriously endangers public health safety. As a first-line drug used in clinical practice, tenofovir alafenamide fumarate (TAF) has the characteristics of strong efficacy, low drug resistance, and bone and kidney safety. This article summarizes the role of TAF in patients with special types of chronic hepatitis B, such as low-level viremia, multidrug resistance, pregnancy, liver failure, and liver transplantation, and the analysis shows that TAF can reduce viral load in patients with low-level viremia to achieve virologic response, provide new regimens for patients with drug resistance, block mother-to-child transmission, reduce the mortality rate of patients with end-stage liver disease, and improve renal function in patients with chronic kidney disease.
